Longboard Pharmaceuticals, Inc. (LBPH)

20,34 -0,48 (-2,31%) Börsenschluss: 04:00PM EDT

Longboard Pharmaceuticals, Inc.

4275 Executive Square
Suite 950
La Jolla, CA 92037
United States
858-789-9283
https://www.longboardpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 50

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Kevin R. Lind	President, CEO, Secretary & Director	1,07M	N/A	1976
Ms. Brandi L. Roberts CPA, M.B.A.	Executive VP & CFO	662,65k	N/A	1974
Dr. Randall E. Kaye M.D.	Executive VP & Chief Medical Officer	717,95k	N/A	1962
Mr. Chadwick J. Orevillo MPH	Executive VP & Head of Operations	N/A	N/A	N/A
Megan E. Knight	VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Steven W. Spector J.D.	Executive VP, Head of Business Development & General Counsel	N/A	N/A	1965
Dr. Anne M. Danks Ph.D.	VP & Head of Nonclinical Research & Development	N/A	N/A	N/A
Mr. Gus Cardenas	VP & Head of Quality Assurance	N/A	N/A	N/A
Dr. Marco Peters Ph.D.	VP & Head of Translational Science	N/A	N/A	N/A
Dr. Dewey McLin Ph.D.	VP & Head of Medical Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Corporate Governance

Longboard Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 9. Die grundlegenden Scores sind Audit: 7, Vorstand: 10, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.